Announcement PDF Atomo Diagnostics Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Atomo Diagnostics Limited ABN: 37 142 925 684 Reporting period: For the period ended 30 June 2026 Previous period: For the period ended 30 June 2025 2. Results for announcement to the market AUD Revenue from ordinary activities up 41% to 5,333,849 Loss from ordinary activities after tax attributable to the owners of Atomo Diagnostics Limited down 29% to 3,513,587 Total comprehensive loss from the period attributable to the owners of Atomo Diagnostics Limited down 30% to 3,423,464 30 June 2026 30 June 2025 AUD Cents AUD Cents Basic Loss per share (0.425) (0.768) Diluted Loss per share (0.425) (0.768) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the group after providing for income tax amounted to AUD3,513,587 (30 June 2025: AUD4,970,934). Refer to the 'Operating and Financial Review' within the Directors' Report for further commentary on the full-year's results, financial position and likely developments in future years. 3. Net tangible assets Consolidated 30 June 2026 30 June 2025 AUD AUD Net tangible asset per ordinary security 0.72 0.72 The net tangible assets per ordinary security is calculated based on 902,432,853 ordinary shares on issue as at 30 June 2026 , and 739,115,183 ordinary shares that were on issue as at 30 June 2025. 4. Loss of control over entities Not applicable. 5. Details of associates and joint venture entities Not applicable. 6. Audit qualification or review The financial statements have been audited and an unmodified opinion has been issued. Atomo Diagnostics Limited Appendix 4E Preliminary final report 7. Attachments The Annual Report of Atomo Diagnostics Limited for the period ended 30 June 2026 is attached. 8. Annual General Meeting Atomo Diagnostics advises that its Annual General Meeting will be held on or about 5 November 2026. The time and other details relating to the Meeting will be advised in the Notice of Meeting to be sent to all shareholders and released to ASX immediately after dispatch. In accordance with the ASX Listing Rules, valid nominations for the position of director are required to be lodged at the registered office of the Company by 5.00pm (AEDT) on 17 September 2026. 9. Signed Signed ___________________________ Date: 31 August 2026 Patrick Cook Chair Sydney Atomo Diagnostics Limited ABN 37 142 925 684 Annual Report - 30 June 2026 Atomo Diagnostics Limited Corporate directory For the period ended 30 June 2026 1 Directors Patrick Cook (Non-Executive Director & Chair) John Kelly (Managing Director & CEO - resigned on 19 August 2026) Cheri Walker (Executive Director & Interim CEO) Anthony May (Non-Executive Director) Company secretary Mathew Watkins Registered office Level 1 3 - 5 George Street Leichhardt NSW 2040 Tel: +61 2 9099 4750 Principal place of business Level 1 3 - 5 George Street Leichhardt NSW 2040 Tel: +61 2 9099 4750 Share register Boardroom Pty Limited Level 8 210 George Street Sydney NSW 2000 Tel: +61 2 9290 9600 Auditor BDO Audit Pty Ltd Level 25, 252 Pitt Street Sydney NSW 2000 Solicitors HWL Ebsworth Lawyers Level 14, Australia Square 264 - 178 George Street Sydney NSW 2000 Stock exchange listing Atomo Diagnostics Limited shares are listed on the Australian Securities Exchange (ASX code: AT1) Website www.atomodiagnostics.com Corporate Governance Statement www.atomodiagnostics.com/governance Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 2 Directors The following persons were directors of Atomo Diagnostics Limited during the whole of the financial period and up to the date of this report, unless otherwise stated: Director Appointed Resigned Patrick Cook (Chair & Non-Executive Director) 2 May 2025 n/a John Kelly (Managing Director) 1 April 2010 19 August 2026 Cheri Walker (Executive Director & Interim Chief Executive Officer) 15 November 2022 n/a Anthony May (Non-Executive Director) 2 May 2025 n/a Principal activities The principal activities Atomo Diagnostics Limited ("Atomo" or "group") during the course of the year were the development and sale of medical devices. There were no significant changes in the nature of the activities of the group during the year. Review of operations The loss for the group after providing for income tax amounted to $3,513,587 (30 June 2025:$4,970,934). For the year ended, Atomo recorded revenues of $5,333,849, largely comprising of POC Test sales for HIV of $2,840,399, POC technology sales of $2,150,773 and $342,677 from development fees and other revenue. An increase of 41% from comparative period. Despite increase revenue, margin reduced from 51% to 35%, driven mainly by one-off licence fees received in the comparative period. Other income for the period was $2,234,374, largely comprising of R&D rebate $1,260,540 and recognition of $886,925 for government grant activities undertaken for the development of Syphilis Test, offsetting a portion of eligible operating costs. Ongoing measures throughout the period relating to operating expense management, has resulted in continued reduction in overhead expenditure for the group. Overall operating expense reduced over $781,233 from comparative period, equivalent to a 9% reduction, maintaining lean operations in the period and reflecting a concerted effort over the last three years to reduce costs across the business. From capital raising activities during the period, Atomo successfully raised Atomo $4,059,742 as at 30 June 2026 net of transaction costs. Capital raised will focus on expanding Atomo's portfolio of products and technology platforms, investing prudently in areas of the business to support market facing commercial activities and measures to reduce operating COGS to improve margins. Atomo continued to build momentum across government-funded HIV self-testing programs, supported by growing recognition of self- testing as an important component of HIV management strategies. During the period, the Atomo achieved growth across Europe and secured significant orders in low- and middle-income country (LMIC) public health markets. Combined with ongoing expansion of funded programs, these developments contributed to a 21% year-on-year increase in HIV-related revenue (Point-of-care tests). During the period, Atomo's strategic partner, Lumos Diagnostics Limited (ASX: LDX), secured a six-year exclusive US distribution agreement for its FebriDx Test with PHASE Scientific. FebriDx is delivered to the end user using Atomo's patented Pascal cassette, and the product's US regulatory approvals are dependent on the Pascal device's performance, making Atomo a critical supplier to Lumos under this agreement. The contract is valued at up to US$316 million in FebriDx revenues over the six-year term, subject to Lumos achieving the contract's minimum order quantities. As a result, Atomo experienced a substantial increase in orders from Lumos during the year, with order volumes increasing more than nine-fold compared to the prior year. Combined with overall sales increased 209% for Point-of-care technology year-on-year. Cash and cash equivalents at 30 June 2026 amounted to $3,708,792 compared to $3,219,646 as at 30 June 2025. Significant changes in the state of affairs ● On 3 July 2025, Atomo completed the issue of the remaining 31,729,730 Placement shares under Tranche 2 of the placement announced in April 2025. The shares were issued at $0.0185 per share, raising approximately $567,000. Participating investors also received one attaching option for every share issued, exercisable at $0.04 and expiring three years from the date of issue. ● Following shareholder approval obtained at the Extraordinary General Meeting held on 26 June 2025, Atomo proceeded to place the remaining shortfall under its Share Purchase Plan (SPP). On 24 July 2025, the Company completed the first tranche of the SPP shortfall placement, issuing 16,810,814 shares at $0.0185 per share and raising $311,000. Remaining SPP shortfall was placed on 14 August 2025, for the amount of $416,612, issuing 22,519,555 shares to investors. The investors also received one attaching option for each share issued, exercisable at $0.04 and expiring three years from the date of issue. ● On 30 March 2026, Atomo completed a Placement to institutional and sophisticated investors at $0.033 per share plus the issuance of 1 option for every 2 shares at a strike price of $0.045 (with a 2.5 year expiry date from option issue date). Placement raised was $3,000,000, issuing 90,909,091 shares. Following, on 15 May 2025, SPP was completed with same terms, raising a further $45,000 issuing 1,348,480 shares. There were no other significant changes in the state of affairs of the group during the financial period. Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 3 Matters subsequent to the end of the financial period On 19 August 2026, Atomo announced John Kelly stepping down from his role as Managing Director, effective 19 August 2026, following a Board decision to reposition the Company's executive leadership to reflect its evolving international commercial footprint. As part of the leadership transition, the Board appointed US-based Cheri Walker, a current Director of the Company, as Interim Chief Executive Officer, effective 19 August 2026. No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the group's operations, the results of those operations, or the group's state of affairs in future financial years. Likely developments and expected results of operations With approximately $3,708,792 of cash at bank and no debt, Atomo continues to pursue its key priorities while remaining focused on conserving capital over the medium term. ● Continued rollout and growing momentum of HIV Self-Testing sales globally in developed markets throughout Europe, Australia and New Zealand. ● Focus on the expansion of Atomo's Point-of-Care (POC) cassette supply business, especially in the US market where the successfully CLIA-Waiver for Lumos’s FebriDx test on Pascal locks significant contracted volumes for supply of FebriDx to PHASE. This regulatory approval also provides a predicate pathway for new Diagnostics partners seeking a proven solution to enter valuable CLIA-waived and self-test channels for the rapid blood tests. ● Growing the emerging development services business where Atomo is being paid to develop products and custom solutions for partners seeking access to Atomo technology and products. ● Improved operating margins across the business resulting for Atomo bringing critical operations such as its proprietary blister manufacturing in-house along with the qualification of high cavitation tooling improving Cost of Goods (COGs). Business risk The group has identified the following material business risks that may cause its revenue and profitability to decline and are important to key stakeholders such as investors, consumers, customers, supplier, governments and employees. ● Regulatory risk: The group sells medical devices and finished products that require regulatory approvals to be maintained (for existing approved products), and to be obtained (for new products) in multiple jurisdictions. This includes obtaining and maintaining product approvals from the TGA in Australia, the FDA in the US, Health Canada in Canada, comparable bodies in Asia and South America, the World Health Organisation for LMIC global health markets, and compliance with the IVDD and IVDR regimes in Europe. There are risks associated with these regulatory approvals that may impact on the business should approvals be withdrawn for existing products or not obtained for new products. ● Product quality and safety: Should quality or safety issues arise with Atomo's products, there is the potential for negative financial and or reputational impacts. To mitigate this risk Atomo sources materials from quality suppliers, complies with ISO 13485 Medical Devices Quality Management, and delivers safe products to customers. Atomo aims to adhere to or exceed strict regulatory standards in all jurisdictions that it serves, and investigates all concerns to ensure our products maintain the highest quality. We are frequently inspected by independent regulatory authorities auditing compliance with these standards. ● Compliance: Responsibility to drive compliance with legal and regulatory requirements applicable to our global business. Includes development of policies and controls, communication and training, oversight and continuous improvement. Consequently, compliance affects every aspect of what we do, to deliver quality products to consumers. ● Supply chain: Responsibility to partners to ensure our product line is free from human rights concerns such as forced labour and trafficking, unsafe labour standards and unfair treatment. Atomo relies on third party manufacturers in certain areas and as such has potential exposure to supply chain disruption risks. The company takes steps to stay closely engaged with its supply chain and ensures sufficient stock on hand to mitigate this risk. ● Employees and skilled labour: Atomo's business relies on key qualified personnel. Ensuring our employees are appropriately remunerated and work in a safe environment, which meets or exceeds relevant regulatory expectations, addresses health and safety concerns as they arise and mitigates the risk of reoccurrence of incidents. ● Operational risk: Atomo has international operations, including a manufacturing facility in South Africa and as such is potentially exposed to additional from political, legal, economic and regulatory risk specific to those locations. ● Atomo operates in a competitive industry: Strategies and initiatives designed to provide diagnostics at competitive prices to ensure it can develop, manufacture and market high-quality generic and branded products, with a particular focus on accessible diagnostics for the global health and Lower and Middle Income markets. ● Corruption and bribery: Business must be conducted with transparency, and free from unethical persuasion. Ethical business practices relate to every aspect of Atomo's business, from identifying product sources, through the development of diagnostics, transactions with regulatory bodies and sale to customers. ● Resource use and waste management: Includes energy usage during manufacture and logistics, water usage and waste as a by-product of manufacture, with particular consideration given to the fact that the products are classified as medical waste upon use. ● Climate risk: The board is considering on an ongoing basis the potential response to climate risk and considering potential implementation of a formal review and policy response in future years. The Board believes that the group has adequate systems in place for the management of its exposure to business risk. The group's operations are not subject to any significant environmental regulation under Australian Commonwealth or State law. Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 4 Information on directors Name: Patrick Cook Title: Non-Executive Director and Chair (appointed Chair on 9 September 2025) Experience and expertise: An experienced Non-Executive Director and Chair with over 35 years experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. Previously served as Non-Executive Director at Workplace Drug Testing Australasia Ltd, Non- Executive Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of Australia (Qld), a Fellow of the Australian Institute of Company Directors and holds degrees in Science and Marketing. Other current directorships: Nil Former directorships (last 3 years): Non-Executive Director & Chair at Workplace Drug Testing Australasia Ltd Non-Executive Director & Chair at eWaste Connection Ltd Special responsibilities: Member of Audit and Risk Committee Interests in shares: 717,909 Interests in options: 1,940,541 Contractual rights to shares: Nil Name: John Kelly Title: Interim Chair (from 23 May 2025 to 9 September 2025) Managing Director and CEO (Resigned on 19 August 2026) Experience and expertise: During the period, John Kelly was the Managing Director and CEO of Atomo. During the period John Kelly was also appointed as Interim Chair of Atomo. For 25 years Mr Kelly has focused on developing and commercialising innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing ‘Unifill’, the world’s first glass prefilled drug delivery device with integrated auto retract safety feature, and this technology was successfully licensed to Sanofi Aventis. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the ground-breaking Mirage Swift and Activa mask systems. Mr Kelly holds an Honours degree in Mechanical Engineering from the University of Liverpool, a Master’s degree in Manufacturing Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney, where he was awarded the Business School’s inaugural ‘Excellence in Leadership’ scholarship. Other current directorships: Non-Executive Director - Tetratherix Limited Former directorships (last 3 years): Nil Special responsibilities: Nil Interests in shares: 74,111,870 Interests in options: 1,621,622 Contractual rights to shares: Nil Name: Cheri Walker Title: Executive Director Interim Chief Executive Officer (Appointed on 19 August 2026) Experience and expertise: Dr. Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the Interim Chief Executive Officer of Atomo Diagnostics and was previously CEO of Zeta Corporation, CEO Founder of Rhinostics, and CFO of Kailos Genetics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. Dr. Walker holds a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College. Other current directorships: Nil Former directorships (last 3 years): Nil Special responsibilities: Member Audit and Risk Committee Interests in shares: Nil Interests in options: 1,000,000 Contractual rights to shares: Nil Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 5 Name: Anthony May Title: Non-Executive Director Experience and expertise: Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With extensive experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a strong track record in business leadership and strategic growth. Mr May is a member of the Australasian Association for Clinical Biochemistry and Laboratory Medicine and holds a bachelor’s degree in science. Other current directorships: Nil Former directorships (last 3 years): Nil Special responsibilities: Chair of Audit and Risk Committee Interests in shares: 540,541 Interests in options: 1,240,541 Contractual rights to shares: Nil 'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated. Company Secretary Mr Watkins is a Chartered Accountant who has extensive ASX experience within several industry sectors including Biotechnology, Bioscience, Resources and Information Technology. He specialises in ASX statutory reporting, ASX compliance, Corporate Governance and board and secretarial support. Mr Watkins is appointed Company Secretary on a number of ASX listed Companies. Mr Watkins is employed at Vistra Australia Pty Ltd (Vistra) and currently Australian Market Lead of Vistra. Vistra is a prominent provider of specialised consulting and administrative services to clients in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Mr Watkins was appointed as Atomo’s Company Secretary on 9 June 2024. Meetings of directors The number of meetings of the company's Board of Directors ('the Board') held during the period ended 30 June 2026, and the number of meetings attended by each director were: Full Board Audit and Risk Committee Attended Held1 Attended Held1 Patrick Cook2 7 7 3 3 Cheri Walker4 7 7 3 3 Anthony May 7 7 3 3 John Kelly3 7 7 3 3 1 Represents the number of meetings when the director was eligible to attend as a member of the relevant committee. 2 Appointed Chair on 9 September 2025 3 Resigned Interim Chair on 9 September 2025 and resigned from Managing Director and Chief Executive Officer on 19 August 2026 4 Appointed Interim Chief Executive Officer on 19 August 2026 Remuneration report (audited) The remuneration report details the key management personnel remuneration arrangements for the group, in accordance with the requirements of the Corporations Act 2001 and its Regulations. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all directors. The key management personnel of the group during the financial year consisted of the following Directors of the Company: ● Patrick Cook – Non-Executive Director and Chair (Appointed Chair on 9 September 2025) ● John Kelly – Managing Director and Chief Executive Officer (Resigned on 19 August 2026) & Interim Chair (from 23 May 2025 to 9 September 2025) ● Cheri Walker – Executive Director & Interim Chief Executive Officer (Appointed on 19 August 2026) ● Anthony May – Non-Executive Director And the following executives: ● Chandra Sukumar – Chief Operating Officer Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 6 The remuneration report is set out under the following main headings: ● Remuneration Governance ● Principles used to determine the nature and amount of remuneration ● Details of remuneration ● Service agreements ● Share-based compensation ● Additional disclosures relating to key management personnel ● Statutory performance indicators Remuneration Governance The function and responsibilities in respect of remuneration and nomination related matters is fulfilled by the Board in relation to: (i) recruitment, retention and termination policies and practices for Executive Directors and direct reports to the Managing Director and the alignment of the policies and practices with the promotion and sustainment of a culture aligned with Atomo's values, the promotion of long term sustainable success and the achievement of the company's business objectives; (ii) people strategies and practices which will instil and reinforce the Company’s purpose and values, ensure health and wellbeing (physical and mental) and support the achievement of the company's long term business objectives; (iii) the development of, and progress in meeting, the Company’s diversity objectives; and (iv) the Company’s performance appraisal processes for the Managing Director and the Managing Director’s direct reports, the Board, Board Committees and individual Non-Executive Directors. The Audit Risk Committee (ARC), is the only sub-committee of the Board. The members of the ARC at the date of this report is as follows: ● Anthony May (Chair) ● Cheri Walker (Chair up to 19 August 2026) ● Patrick Cook The role and responsibilities, composition, structure and membership requirements of the PCNRC (currently fulfilled by the Board) are documented in the People, Culture, Nomination and Remuneration Committee Charter which is available on Atomo’s website at: https://atomodiagnostics.com/governance/. Principles used to determine the nature and amount of remuneration Non-executive directors remuneration Each of the Non-Executive Directors has entered into appointment letters with Atomo confirming the terms of their appointment and their roles and responsibilities. The appointment letters are on standard commercial terms. Directors may also be reimbursed for expenses properly incurred by them in dealing with the Company’s business or in carrying out their duties as a Director. Under the Constitution, the Board decides the amount paid to each Non-Executive Director as remuneration for their services as a Director. However, under the ASX Listing Rules, the total amount of fees paid to all Non-Executive Directors for their services must not exceed in aggregate in any financial year the amount fixed by the Company’s shareholders in general meeting. This amount has been fixed initially in the Company’s Constitution at $500,000 per annum in aggregate and may be varied by ordinary resolution in a general meeting. Executive remuneration The group aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components. The executive remuneration and reward framework has four components: ● base pay ● short-term performance incentives ● share-based payments ● other remuneration such as superannuation and long service leave The combination of these comprises the executive's total remuneration. Fixed remuneration, consisting of base salary and superannuation are reviewed annually by the Board based on individual and business unit performance, the overall performance of the group and comparable market remunerations. Executives may receive their fixed remuneration in the form of cash or other benefits where it does not create any additional costs to the group and provides additional value to the executive. The short-term incentives ('STI') program is designed to align the targets of the business units with the performance hurdles of executives. STI payments are granted to executives based on specific annual targets and key performance indicators ('KPI's') being achieved. Details of STIs paid to executives during the year can be found under the heading "Amounts of remuneration" below. Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 7 The long-term incentives ('LTI') include long service leave and share-based payments. Further details in relation to Atomo’s Employee Share Option Plan ('ESOP') can be found under the heading “Share-based compensation” below. During the financial period ended 30 June 2026, the group, through the Board Committee, engaged SLM Corporate, remuneration consultants, to undertake an independent review of executive remunerations. The review assessed current executive remuneration against relevant market benchmarks and concluded that remuneration levels were withing appropriate market ranges. SLM Corporate was paid $7,150 for these services. Details of remuneration Amounts of remuneration Details of the remuneration of key management personnel of the group are set out in the following tables. Short-term benefits Post- employment benefits Long-term benefits Share-based payments Cash salary Cash Non- Super- Long service Equity- and fees bonus monetary annuation leave settled Total 30 June 2026 AUD AUD AUD AUD AUD AUD AUD Non-Executive Directors: Patrick Cook1 43,750 - - - - 40,632 84,382 Cheri Walker3 50,000 - - - - 29,023 79,023 Anthony May 39,063 - - 4,688 - 20,316 64,067 Executive Directors: John Kelly2 396,969 28,710 - 30,000 20,271 - 475,950 Other Key Management Personnel: Chandra Sukumar 274,015 59,625 - 30,000 10,145 - 373,785 803,797 88,335 - 64,688 30,416 89,971 1,077,207 1 Appointed Chair on 9 September 2025 2 Resigned Interim Chair on 9 September 2025 and resigned from Managing Director & Chief Executive Officer on 19 August 2026 3 Appointed Interim Chief Executive Officer 19 August 2026 Short-term benefits Post- employment benefits Long-term benefits Share-based payments Cash salary Cash Non- Super- Long service Equity- and fees bonus monetary annuation leave settled Total 30 June 2025 AUD AUD AUD AUD AUD AUD AUD Non-Executive Directors: Patrick Cook1 4,167 - - - - - 4,167 Cheri Walker 50,000 - - - - - 50,000 Anthony May1 3,737 - - 430 - - 4,167 John Keith2 108,333 - - - - - 108,333 Paul Kasian2 52,317 - - 6,016 - - 58,333 Deborah Neff2 75,000 - - - - - 75,000 Executive Directors: John Kelly3 415,427 - - 29,932 (19,568) - 425,791 Other Key Management Personnel: Chandra Sukumar 265,520 - - 29,932 21,405 - 316,857 974,501 - - 66,310 1,837 - 1,042,648 1 Appointed on 2 May 2025 2 Resigned on 2 May 2025 3 Appointed Interim Chair on 23 May 2025 Atomo Diagnostics Limited Directors' report For the period ended 30 June 2026 8 The proportion of remuneration linked to performance and the fixed proportion are as follows: Fixed remuneration At risk - STI At risk - LTI Name 30 June 2026 30 June 2025 30 June 2026 30 June 2025 30 June 2026 30 June 2025 Non-Executive Directors: Patrick Cook1 & 4 100% 100% - - - - Cheri Walker5 100% 100% - - - - Anthony May1 100% 100% - - - - John Keith2 - 100% - - - - Paul Kasian2 - 100% - - - - Deborah Neff2 - 100% - - - - Executive Directors: John Kelly3 77% 100% 23% - - - Other Key Management Personnel: Chandra Sukumar 79% 100% 21% - - - 1 Appointed on 2 May 2025 2 Resigned on 2 May 2025 3 Appointed Interim Chair on 23 May 2025 to 9 September 2025 and resigned from Mana